A. Joly

发表

CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation*

A Joly, N S Gray, P G Schultz, 1997, The Journal of Biological Chemistry.

A New Structural Class of Proteasome Inhibitors that Prevent NF-κB Activation

M. Wick, A. Joly, S. Kerwar, 1998 .

A new structural class of proteasome inhibitors that prevent NF-kappa B activation.

M. Wick, A. Joly, S. Kerwar, 1998, Biochemical pharmacology.

Fibroblasts Promotes Mammary Tumorigenesis Receptor Knockout Β Transforming Growth Factor- Enhanced Hepatocyte Growth Factor Signaling by Type Ii Updated Version Material Supplementary Cited Articles Citing Articles E-mail Alerts Enhanced Hepatocyte Growth Factor Signaling by Type Ii Transforming Gr

Y. Shyr, H. Moses, A. Joly, 2007 .

Neutral lipid from proteinuric rat urine is a novel inhibitor of the red blood cell calcium pump.

A. Joly, A. Lindner, T. Hinds, 1999, Journal of the American Society of Nephrology : JASN.

Evidence for inflammatory and secretagogue lipids in cyst fluids from patients with autosomal dominant polycystic kidney disease.

L. Rome, J. Grantham, A. Joly, 1997, Proceedings of the Association of American Physicians.

Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.

J. Hughes, A. Joly, D. Kerjaschki, 2001, Journal of the American Society of Nephrology : JASN.

Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.

Y. G. Kim, J. Abraham, J. Hughes, 2001, Kidney international.

Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts.

V. Hwa, A. Joly, S. Twigg, 2002, Endocrinology.

Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF‐κB activation

A. Joly, S. Meyer, N.Gail Kohler, 1997, FEBS letters.

N-acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kappaB activation and prevents TNF and IL-6 synthesis in vivo.

A. Joly, S. Schow, 1997, Cellular immunology.

Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay.

A. Joly, K. McMillan, Wentao Zhang, 2007, Assay and drug development technologies.

Effect of site-directed mutagenesis of conserved aspartate and arginine residues upon farnesyl diphosphate synthase activity.

P. Edwards, A. Joly, 1993, The Journal of biological chemistry.

In vitro identification of a soluble protein:geranylgeranyl transferase from rat tissues.

P. Edwards, A. Joly, G. Popják, 1991, The Journal of biological chemistry.

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Experimental Therapeutics, Molecular Targets, and Chemical Biology

K. Yamaguchi, J. Greshock, R. Wooster, 2009 .

Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus.

A. Joly, S. Twigg, R. Rosenfeld, 2001, Endocrinology.

The Involvement of an LPS Inducible IκB Kinase in Endotoxin Tolerance

A. Joly, Kohler Ng, 1997 .

Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides.

M. Wick, A. Joly, R. Lum, 1998, Bioorganic & Medicinal Chemistry Letters.

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yongchang Shi, Yu-Chien Chou, K. Yamaguchi, 2011, Molecular Cancer Therapeutics.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes, A. Joly, Lora Zhao, 2013, Thyroid : official journal of the American Thyroid Association.

Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.

Y. Shyr, H. Moses, A. Joly, 2007, Cancer research.

Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion

Y. Shyr, H. Moses, A. Joly, 2008, Molecular Cancer Research.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

K. Yamaguchi, J. Greshock, R. Wooster, 2009, Cancer research.

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

F. Yakes, A. Joly, J. Martini, 2007, Clinical Cancer Research.

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

M. Reiss, A. Joly, K. Reiss, 2004, Biochemical pharmacology.

CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis.

J. Abraham, A. Joly, G. Schreiner, 2000, Journal of molecular and cellular cardiology.

Inhibition of the mitogen activated protein kinase, p38α, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading

A. Joly, G. Schreiner, S. Chakravarty, 2001 .

Synthesis and activity of 2,6,9-trisubstituted purines

M. Wick, A. Joly, S. Kerwar, 1997 .

Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth

K. Yamaguchi, J. Lesch, F. Yakes, 2011 .

Structure-based secondary structure-independent approach to design protein ligands: Application to the design of Kv1.2 potassium channel blockers.

A Joly, P Cuniasse, M. Lefranc, 2006, Journal of the American Chemical Society.

Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.

Y. Shyr, H. Moses, A. Joly, 2008, Molecular cancer research : MCR.

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

K. Yamaguchi, F. Yakes, A. Joly, 2011, Molecular Cancer Therapeutics.

Insulin-like growth factor-binding protein-3 induces fetalization in neonatal rat cardiomyocytes.

J. Abraham, L. Stanton, A. Joly, 2000, DNA and cell biology.

Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion

Y. Shyr, H. Moses, A. Joly, 2008, Molecular Cancer Research.